Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.

Citation metadata

Date: Jan. 5, 2021
Publisher: BioMed Central Ltd.
Document Type: Correction notice; Brief article
Length: 217 words
Lexile Measure: 1220L

Document controls

Main content

Abstract :

An amendment to this paper has been published and can be accessed via the original article.

Source Citation

Source Citation   

Gale Document Number: GALE|A650588106